Urolithin A exerts antiobesity effects through enhancing adipose tissue thermogenesis in mice
Fig 1
UA prevents HFD-induced obesity and hyperglycemia in mice.
(A) Schematic diagram of mice treatment. Six pairs of C57BL/6 male mice fed an HFD were treated with 30 mg/kg/day of UA or vehicle by gavage starting from 8 weeks of age for a period of 10 weeks. (B) Body weight time course. (C) Body composition measured by DEXA scan after 7 weeks of treatment. (D) Cumulative food intake. (E) Levels of fecal TG after 10 weeks of treatment. levels of (F) plasma glucose and (G) insulin after 5 h fasting (n = 6). (H) HOMA-IR index. (I) ITT performed after 6 weeks of treatment and (J) the AUC. (K) GTT performed after 8 weeks of treatment and (L) the AUC. (M) Time course of plasma glucose and GIR during the hyperinsulinemic–euglycemic clamp. (N) Whole-body insulin-stimulated glucose uptake. (O) Insulin-stimulated 2-DG uptake in skeletal muscle, BAT, and WAT. (P) Basal and clamp EGP. The underlying data for this figure can be found in S1 Data. AUC, area under the curve; BAT, brown adipose tissue; DEXA, dual-energy X-ray absorptiometry; EGP, endogenous glucose production; GIR, glucose infusion rate; GTT, glucose tolerance test; HFD, high-fat diet; HOMA-IR, homeostasis model assessment-estimated insulin resistance; ITT, insulin tolerance test; TG, triglyceride; UA, urolithin A; WAT, white adipose tissue; 2-DG, 2-deoxyglucose.